Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combretastatin A4 phosphate.

Catharine M L West1, Pat Price

  • 1Academic Department of Radiation Oncology and Manchester Molecular Imaging Centre, University of Manchester, Christie NHS Trust Hospital, Wilmslow Road, Manchester M20 4BX, UK.

Anti-Cancer Drugs
|March 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The UK's radiotherapy workforce shortage: a case for reform.

The Lancet. Oncology·2026
Same author

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Nature communications·2026
Same author

Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity.

Communications medicine·2026
Same author

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.

Nature cancer·2026
Same author

Breast composition and dose deposition to fat and fibroglandular tissues are associated with breast side effects after radiation therapy.

Breast (Edinburgh, Scotland)·2026
Same author

Intra-voxel incoherent motion biomarker repeatability in healthy volunteers and sensitivity to chemoradiotherapy-induced changes in patients with uterine cervical cancer.

Frontiers in oncology·2025
Same journal

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.

Anti-cancer drugs·2026
Same journal

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Anti-cancer drugs·2026
Same journal

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.

Anti-cancer drugs·2026
Same journal

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Anti-cancer drugs·2026
Same journal

Drug repurposing of liver cancer based on multimodal neural network and virtual screening.

Anti-cancer drugs·2026
Same journal

Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.

Anti-cancer drugs·2026
See all related articles

Combretastatin A4 phosphate (CA4P) is a vascular targeting agent that disrupts tumor blood flow by depolymerizing microtubules. Clinical trials show CA4P is safe and effective, especially when combined with other therapies and monitored with imaging.

Area of Science:

  • Oncology
  • Pharmacology
  • Vascular Biology

Background:

  • Combretastatin A4 phosphate (CA4P) is a prodrug of combreastatin A4 (CA4), a microtubule depolymerizing agent.
  • CA4 targets tumor vasculature, causing endothelial cell changes, increased permeability, and disrupted blood flow, leading to tumor necrosis.
  • CA4P demonstrates anti-cancer effects by targeting tumor blood vessels, a mechanism distinct from conventional chemotherapy.

Purpose of the Study:

  • To review the development and clinical application of CA4P as a vascular targeting agent.
  • To elucidate the mechanism of action of CA4P in disrupting tumor vasculature.
  • To summarize the safety, efficacy, and imaging-based monitoring of CA4P in early-phase clinical trials.

Main Methods:

  • Review of preclinical data and early clinical trial results for CA4P.

Related Experiment Videos

  • Description of CA4P's mechanism involving tubulin binding and endothelial cell disruption.
  • Discussion of functional imaging techniques (DCE-MRI, PET) for assessing CA4P's anti-vascular effects.

    • Main Results:

    • CA4P monotherapy is safe in clinical trials and reduces tumor blood flow.
    • Promising efficacy has been observed, particularly when CA4P is combined with therapies targeting the viable tumor rim.
    • CA4P in combination with cisplatin is also safe, with functional imaging aiding dose selection for Phase II trials.

    Conclusions:

    • CA4P is a promising vascular targeting agent with a unique mechanism of action against solid tumors.
    • Combination therapy with CA4P and other anti-cancer treatments enhances efficacy.
    • Functional imaging plays a crucial role in the clinical development and patient selection for CA4P therapy.